PRICE DIFFERENTIAL BETWEEN U.S., U.K. IS SMALLER FOR RECENT PRODUCTS: COULD REPRESENT TREND AWAY FROM UNEQUAL PRICES AMONG DEVELOPED WORLD NATIONS, GAO SAYS
The price differential between newly introduced products in the U.S. and U.K. is smaller than it is for products that have been on the market for more than six years, according to a report by the General Accounting Office released on Feb. 2. The GAO report, requested by House Energy & Commerce/Health Subcommittee Chairman Waxman (D-Calif.), examines the U.S. and U.K. prices of the 77 drugs among the top 200 most frequently dispensed brand name prescription pharmaceuticals in the U.S. that are also marketed in the U.K.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth